A phase 0/I study (NCT04656535) is recruiting recurrent GBM patients to evaluate the safety and tolerability of the anti-TIGIT antibody domvanalimab (AB154) combined with the anti-PD-1 antibody zimberelimab (AB122). The gene discussed is PDCD1; the disease is glioblastoma.